Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by laboratory testing (tissue or cell sample) to have uveal melanoma (a type of eye cancer) that has spread to the liver, and who have been assessed as a suitable candidate for a liver perfusion procedure using a chemotherapy drug called melphalan
• People who have read, understood, and signed the informed consent form after being told about the risks and benefits of the trial in a language they understand
• People who are older than 18 years of age at the time of signing the consent form and are able to follow the trial's requirements
• People who have had a detailed scan of the abdomen (either a CT or MRI scan with contrast dye) within the two months before joining the study
• People who have measurable cancer spread, with at least one affected area that is 1 cm or larger in size and can be reached by a needle biopsy guided by imaging
• People whose life expectancy is expected to be more than 12 weeks
• People who have a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
• People whose recent blood test results meet all of the following requirements: sufficient white blood cell counts, adequate platelet levels, liver enzyme levels within an acceptable range, bilirubin below a certain level, normal blood clotting function, and kidneys working at an adequate level (confirm specific values with the trial site)

Who may not be able to join:

• People where the area of cancer chosen for biopsy has previously been treated with radiation therapy or other local treatments
• People still experiencing significant side effects from a previous chemotherapy treatment (minor side effects such as hair loss are generally not excluded — confirm with trial site)
• People who have taken high-dose steroid medications (such as prednisone or dexamethasone) or other immune-suppressing medications above a certain daily dose within the two weeks before the trial starts, or who are expected to need such medications during the trial (short one-time doses for nausea or reactions to contrast dye may be acceptable — confirm with trial site)
• People taking blood thinning or anti-clotting medications that cannot be safely paused before the biopsy procedure
• People who are pregnant or breastfeeding
• People with any other significant health condition, abnormal test result, or finding that could make the experimental treatment unsafe or affect how the trial results are interpreted
• People who have received certain immune-stimulating treatments (such as interferon or interleukin-2) within 6 weeks, or within five half-lives of the drug (whichever is the shorter period), before the trial starts
• People who have received immune checkpoint therapy drugs (such as anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-LAG-3 antibodies) within the past three months (prior treatment with a drug called tebentafusp does not require a waiting period — confirm with trial site)
• People who have taken any other experimental medication within at least one month before the biopsy, or within three months if the experimental medication was an immune checkpoint inhibitor (prior treatment with darovasertib and crizotinib does not require a waiting period — confirm with trial site)
• People showing clear signs or symptoms of an infection within the two weeks before the trial starts

Important: Always verify eligibility with the trial site directly before applying.